METHOD DEVELOPMENT AND VALIDATION STUDY FOR QUANTITATIVE DETERMINATION OF GENOTOXIC IMPURITY AND ITS PRECURSOR IN FLUCONAZOLE SAMPLE BY LIQUID CHROMATOGRAPHY–TANDEM MASS SPECTROMETRY
DOI:
https://doi.org/10.22159/ijpps.2016v8i12.14727Keywords:
Fluconazole, Genotoxic Impurity, LCMSMS, Method Development, ValidationAbstract
Objective: The objective of this work is method development and validation study for quantitative determination of 1-[2-(2,4-difluorophenyl)-2,3-epoxypropyl]-1H-1,2,4-triazole, a genotoxic impurity and its precursor in a fluconazole drug sample by liquid chromatography–tandem mass spectrometry.
Methods: LC-MS/MS analysis of these impurities was performed on Hypersil BDS C18 (100 mm x 4.0 mm, 3 µm) column. 5 mmol ammonium acetate and acetonitrile in the ratio of 65:35 (v/v) was used as the mobile phase with a flow rate of 0.4 ml/min. The developed method was accomplished with a short run time of 10 min. Triple quadrupole mass detector coupled with positive electrospray ionization was used for the quantification of genotoxic impurities in multiple reaction monitoring (MRM).
Results: The method was validated as per International Conference on Harmonization (ICH) guidelines. The method was linear in the range of 0.30 µg/g to 11.37 µg/g for impurity A and 0.30 µg/g to 11.34 µg/g for impurity B with a correlation coefficient of 0.999. The accuracy of the method was in the range of 98.25 % to 100.53 % for both impurities.
Conclusion: A specific, selective, highly sensitive and more accurate analytical method using LC-MS/MS coupled with positive electrospray ionization has been developed for the quantification of genotoxic impurity (1-[2-(2,4-difluorophenyl)-2,3-epoxypropyl]-1H-1,2,4-triazole) and its precursor (1-(2,4-difluorophenyl)-2-[1,2,4]triazol-1-yl-ethanone) at 0.3 µg/g with respect to the 5.0 mg/ml of fluconazole.
Downloads
References
Gyorgy Szekely, Miriam C, Amores de Sousa, Marco Gil, Frederico Castelo Ferreira, William Heggie, et al. Genotoxic impurities in pharmaceutical manufacturing: sources, regulations, and mitigation. Chem Rev 2015,115:8182-229.
European Medicines Agency, Evaluation of medicines for human use, the committee for medicinal products for human use (CHMP), Guideline on the limits of genotoxic impurities; 2006. Available from:http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002903.pdf. [Last accessed on 10 Jul 2016]
U S Food and Drug Administration, Guidance for industry genotoxic and carcinogenic impurities in drug substances and products: recommended approaches, 2008. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); 2008.
Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk, M7 ICH Harmonized Tripartite Guideline. Available from: http://www.ich.org/ï¬leadmin/Public_Web_Site/ICHProducts/Guidelines/Multidisciplinary/M7/M7_Step 4.pdf. [Last accessed on 25 Aug 2014]
Rogers TE, Galgiani JN. Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo. Antimicrob Agents Chemother 1986;30:418-22.
Humphrey MJ, Jevons S, Tarbit MH. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob Agents Chemother 1985; 28:648-53.
Pfizer Australia Pty Ltd. Diflucan (Australian Approved Product Information). West Ryde (NSW): Pfizer Australia; 2004.
Vasantha M, Devi AS, Suryanarayana M. Isolation/synthesis and characterization and potential impurities of an antifungal drug, fluconazole. Asian J Biochem Pharm Res 2011;1:201-8.
Muller L, Mauthe RJ, Riley CM, Andino MM, Antonis DD, Beels C, et al. A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity. Regul Toxicol Pharmacol 2006;44:198-211.
Aleksandra F, Darko M, Zdenko H, Marija G, Jelena K, Ranko S, et al. Developmental and transplacental genotoxicology: fluconazole. Mutat Res 2008;657:43-7.
Venugopal N, Reddy AVB, Madhavi V, Reddy KG, Madhavi G, Method development and validation study for quantitative determination of 2-chloromethyl-3, 4-dimethoxy pyridine hydrochloride a genotoxic impurity in pantoprazole active pharmaceutical ingredient (API) by LC/MS/MS. J Pharm Biomed Anal 2012;70:592-7.
Reddy AVB, Venugopal N, Madhavi G, Reddy KG, Madhavi V. A selective and sensitive UPLC–MS/MS approach for trace level quantification of four potential genotoxic impurities in zolmitriptan drug substance. J Pharm Biomed Anal 2013;84:84-9.
Rao MS, Rao SV, Babu KPR, Kumar PS, Sharma HK. Quantification of genotoxic impurities in amlodipine drug substance by LC-MS. Der Pharm Lett 2014;6:47-55.
Reddy AVB, Venugopal N, Madhavi G. A selective and sensitive LC-MS/MS method for the simultaneous determination of two potential genotoxic impurities in celecoxib. J Anal Sci Technol 2014;5:18-25.
Wijk AMV, Beerman B, Niederlander HAG, Siebum AHG, Jong GJD. A new approach for generic screening and quantitation of potential genotoxic alkylation compounds by pre-column derivatization and LC-MS/MS analysis. Anal Bioanal Chem 2011;400:1375-85.
Szekely Gy, Henriques B, Gil M, Ramos A, Alvarez C. Design of experiments as a tool for LC–MS/MS method development for the trace analysis of the potentially genotoxic 4-dimethylaminopyridine impurity in glucocorticoids. J Pharm Biomed Anal 2012;70:251-8.
Wijk AMV, Niederländer HAG, Siebum AHG, Vervaart MAT, Jong GJD. A new derivatization reagent for LC–MS/MS screening of potential genotoxic alkylation compounds. J Pharm Biomed Anal 2013;74:133-40.
Szekely G, Henriques B, Gil M, Alvarez C. Experimental design for the optimization and robustness testing of a liquid chromatography-tandem mass spectrometry method for the trace analysis of the potentially genotoxic 1,3-diisopropylurea. Drug Test Anal 2014;6:898-908.
Durga babu M, Surendrababu K, Kishore M. Development and validation of a gas chromatography-mass spectrometry with selected ion monitoring method for the determination of trace levels of methane sulfonyl chloride as an impurity in itraconazole active pharmaceutical ingredient. Asian J Pharm Clin Res 2016;9:403-7.
Natarajan S, Kempegowda BK, Bharathiar M. Determination of traceable genotoxic impurity chloroacetyl chloride a carcinogen by LC/MS/MS in drug substances. Asian J Pharm Clin Res 2016;9:97-100.
Hermawan D, Ali NAM, Ibrahim WAW, Sanagi MM. Analysis of fluconazole in the human urine sample by high performance liquid chromatography method. J Phys: Conf Ser 2013;423. Doi:10.1088/1742-6596/423/1/012009
Liew KB, Loh GOK, Tan YTF, Peh KK. Development and application of simple HPLC-UV method for fluconazole quantification in human plasma. Int J Pharm Pharm Sci 2012;4:107-11.
Al-rimawi F. Development and validation of analytical method for fluconazole and fluconazole related compounds (A, B, and C) in capsule formulations by HPLC with UV detection. Jordan J Chem 2009;4:357-65.
Dgither SA, Yusuf A, Hammami MM. Fluconazole: stability and analysis in human plasma by simple high performance liquid chromatography. J Pharm Sci 2009;34:179-86.
Kim SD, Im HT, Kang IM, Lee HS, Lee HW, Cho SH, et al. An optimized analytical method of fluconazole in human plasma by high-performance liquid chromatography with ultraviolet detection and its application to a bioequivalence study. J Chromatogr B 2007;852:174-9.
Porta V, Chang KH, Storpirtis S. Evaluation of the bioequivalence of capsules containing 150 mg of fluconazole. Int J Pharm 2005;288:81-6.
Hillis J, Morelli I, Neville D, Fox J, Leary AC. The validation of a bioanalytical method for the determination of fluconazole in human plasma. Chromatographia 2004;59:S203-7.
Abdel-moety EM, Khattab FI, Kelani KM, Aboual-Alamein AM. Chromatographic determination of clotrimazole, ketoconazole and fluconazole in pharmaceutical formulations. Farmaco 2002;57:931-8.
Published
How to Cite
Issue
Section
